A Novel Biomarker for the Diagnosis and Early Detection of Schizophrenia

OCR Number: OCR 5856

Description:

- Biomarkers for psychiatric illnesses do not currently exist and are a critical unmet need.
- Schizophrenia is ranked as the third largest burden among all neuropsychiatric disorders by the World Health Organization's 2002 report.
- Early schizophrenia (prodromal stage) resembles depression and is difficult to accurately diagnose and treat.
- This novel serum biomarker along with another commonly assessed physiological indicator, can differentiate with schizophrenia from healthy patients individuals and those with major depression.
- Initial human proof of concept studies underway to validate.

![Graph showing biomarker levels in healthy control, depressed, and schizophrenic groups.](image)

Stage of Development: Initial human proof of concept studies complete to validate in vivo findings.

Published/Issued Patents: PCT App. Pub. No. WO2014018513

Licensing Contact: Lolahun Kadiri
lolahun.kadiri@yale.edu